CYDY - CytoDyn: Uncovering An Opportunity

I discovered CytoDyn (CYDY) when performing research for an article on Progenics Pharmaceuticals (PGNX). As I was reading through PGNX SEC filings, I saw a few references to Leronlimab (PRO 140), a fully humanized monoclonal antibody treatment for HIV that CytoDyn acquired from Progenics back in 2012. On the word of the deal, Progenics is to collect $5.0M upon FDA approval, along with a 5% royalty of net sales from CytoDyn. When performing research about the treatment, I uncovered a copious amount of positive analysis about PRO 140 from corresponding Seeking Alpha biotech